Clinical trials: completed, sponsored by Bayer
Neoplasms
Japanese BAY1000394 Monotherapy Phase I Study
This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies.
- Trial name
- NCT02047890
- Testing
- BAY1000394 (2.5mg), BAY1000394 (5mg)
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Heart Failure
Multiple Dose Study in Heart Failure of BAY 1067197
This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure.
- Trial name
- PARSiFAL (NCT02040233)
- Testing
- BAY1067197 (10 mg), BAY1067197
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Bayer
Hypertension, Pulmonary
EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
In accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of Adempas in real clinical practice outside the regulated environment of a controlled clinical study.
- Trial name
- EXPERT (NCT02092818)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 28 sites in Argentina, Australia and 26 more
- Volunteers
- 1,316 people
- Sponsor
- Bayer
Rosacea
4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness
The purpose of this study is to evaluate if the test sunscreen skin care product will be well-tolerated and help facial redness when applied to the face after 4 weeks.
- Trial name
- NCT03841032
- Testing
- Coppertone, BAY1183345
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bayer
Neoplasms
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and…
- Trial name
- NCT02106845
- Testing
- Digoxin, Rosuvastatin, Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 42 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable…
- Trial name
- SEARCH (NCT00901901)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva)
- Where
- 127 sites in United States, Australia and 24 more
- Volunteers
- 732 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF)
Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice.
- Trial name
- NCT01598051
- Testing
- Rivaroxaban (Xarelto_ BAY59-7939)
- Where
- Japan
- Volunteers
- 741 people
- Sponsor
- Bayer
Drug Interactions
Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants
BAY1902607 is a new type of drug under clinical development for different conditions including the treatment of endometriosis, i.e. a condition where the tissue that usually grows inside the womb grows outside of the womb.
- Trial name
- NCT03789890
- Testing
- BAY1902607, Itraconazole
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
The purpose of this study is to obtain long-term clinical data from patients approximately 15 years after their first clinical event, who participated in the former BENEFIT 304747 study and were treated at least once within that…
- Trial name
- NCT03269175
- Testing
- Brain MRI, Blood sampling
- Where
- 61 sites in Austria, Belgium and 16 more
- Volunteers
- 261 people
- Sponsor
- Bayer
Leukemia, Myeloid, Acute
BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)
To determine the maximum tolerated and / or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical…
- Trial name
- NCT03127735
- Testing
- BAY1436032
- Where
- 13 sites in United States, Germany
- Volunteers
- 27 people
- Sponsor
- Bayer
Clinical Trials, Phase I as Topic
BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect
This study is a first-in-man study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1902607 using a placebo controlled, randomized, single center design.
- Trial name
- NCT03212586
- Testing
- BAY1902607
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Hypogonadism
Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone
We will investigate if testosterone is preferentially given to patients at higher risk of cardiovascular events. If this is the case, then observational studies may be prone to selection bias resulting in overestimation of the…
- Trial name
- NCT03484260
- Testing
- Testosterone Product
- Where
- Germany
- Volunteers
- 27,778 people
- Sponsor
- Bayer
Prostatic Neoplasms
Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo.
- Trial name
- NCT02788409
- Testing
- Not applicable for study
- Where
- United States
- Volunteers
- 2,234 people
- Sponsor
- Bayer
Contraception
Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy
Qlaira is a combined oral contraceptive (COC) containing dienogest/estradiol valerate being the first oral contraceptive delivering estradiol. It has been recently approved in Mexico.
- Trial name
- NCT01602770
- Testing
- EV/DNG (Qlaira, BAY86-5027)
- Where
- Mexico
- Volunteers
- 1 people
- Sponsor
- Bayer
Pharmacology, Clinical
Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations
Primary Objective: To compare the bioavailability of a single dose of fluconazole 150 mg capsules (Test product) with the bioavailability of a single dose of Diflucan™ capsules, 150 mg (Reference) administered under fasting…
- Trial name
- Orca (NCT03929861)
- Testing
- Fluconazole (BAYT006267) 150 mg capsules, Fluconazole 150 mg capsules (DiflucanTM)
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bayer
Pulmonary Hypertension
Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
This is an open-label, uncontrolled, prospective long-term observation of Specific Drug in the treatment of patients with pulmonary hypertension up to 4 years.
- Trial name
- OPTION (NCT01389271)
- Testing
- Ventavis inhaled (Iloprost, BAYQ6256)
- Where
- Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Bayer
Atrial Fibrillation
Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies
This prospective observational study is to assess the predictive factors of poor control of international normalized ratio (INR) to determine the treatment strategies received by patients with a poor control of INR in real-life…
- Trial name
- SULTAN (NCT02610153)
- Testing
- Vitamin K Antagonist
- Where
- Spain
- Volunteers
- 1,013 people
- Sponsor
- Bayer
Heart Failure
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
- Trial name
- PANTHEON (NCT02992288)
- Testing
- Neladenoson bialanate (BAY1067197)
- Where
- 75 sites in United States, Belgium and 9 more
- Volunteers
- 427 people
- Sponsor
- Bayer
Colorectal Neoplasms
Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
This is an open-label phase III study of regorafenib in patients with metastatic colorectal cancer (mCRC) who have progressed after all approved standard therapy.
- Trial name
- REGARD (NCT01853319)
- Testing
- Regorafenib (Stivarga, BAY73- 4506)
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Bayer
Thrombosis
Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children
To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability
- Trial name
- NCT02497716
- Testing
- Rivaroxaban (Xarelto, BAY59-7939
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 47 people
- Sponsor
- Bayer